Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9824928 | 0.79 | — | — | |
| SCHEMBL21653969 | 0.78 | KDM4E (0.33) | ALOX5KDM4ELMNA | |
| SCHEMBL13974622 | 0.77 | — | — | |
| SCHEMBL14140869 | 0.75 | — | — | |
| SCHEMBL20243974 | 0.74 | — | — | |
| SCHEMBL11306795 | 0.74 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL22281760 | 0.72 | CHRNA4 (0.30) | — | |
| SCHEMBL25990803 | 0.72 | LMNA (0.46) | KDM4ELMNA | |
| SCHEMBL8008534 | 0.72 | — | — | |
| SCHEMBL14315288 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524959-B1 | Indole and azaindole inhibitors of pad enzymes | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-12-13 | — | — | US | disclosed |
| US-11192891-B2 | Diazaspiro ROCK inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-12-07 | — | — | US | disclosed |
| US-20210188848-A1 | DIAZASPIRO ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-24 | — | — | US | disclosed |
| EP-3219709-A1 | INTERMEDIATE COMPOUND OF MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2017-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524959-B1 | Indole and azaindole inhibitors of pad enzymes | PADI4, PADI1, PADI2 | ALOX5 890/4885KDM4E 50/4885LMNA 3564/4885 |
| US-11192891-B2 | Diazaspiro ROCK inhibitors | ROCK1, MYLK, ROCK2 | ALOX5 196/4885KDM4E 949/4885LMNA 1873/4885 |
| US-20210188848-A1 | DIAZASPIRO ROCK INHIBITORS | ROCK1, MYLK, ROCK2 | ALOX5 196/4885KDM4E 949/4885LMNA 1873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.